FDA-filed SPL labeling · retrieved through openFDA

Paricalcitol

Paricalcitol is a synthetic vitamin D analog used to prevent and treat secondary hyperparathyroidism (overactive parathyroid glands) caused by chronic kidney disease.

Brand name Zemplar
Drug classes ⓘ Vitamin D2 Analog
Rx Forms 2 Routes Intravenous · Oral
Dr. Brian Staiger, PharmD, BCPS
Reviewed by Last reviewed Jul 10, 2026
🧬 Where this information comes from Click to expand

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 11 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →

At a glance
Linked label effectiveAug 7, 2024
Clinical labels in scope ⓘ11
AvailabilityRx
Earliest approval/marketing year ⓘ1998
FDA-listed product records ⓘ111
Boxed warningNone found in compared labels
How we combine label and product data →
⭐ Paricalcitol at a glance The quick version — the full detail is in the Patient Information Guide below.
💊
HelloPharmacist Editorial Team Bottom Line
Paricalcitol is a prescription vitamin D analog that helps control overactive parathyroid glands in people with chronic kidney disease. It requires regular blood test monitoring for calcium and PTH to keep levels in a safe range. Take it exactly as prescribed, and report any symptoms of high calcium — such as unusual tiredness, confusion, or excessive thirst — to your doctor right away.
How we write & review this content — our editorial policy →

📖 Paricalcitol: Patient Information Guide

A plain-language walkthrough of Paricalcitol — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.

🎯What it's used for▾

Paricalcitol is a vitamin D analog approved to prevent and treat secondary hyperparathyroidism — an overproduction of parathyroid hormone (PTH) that develops as a result of chronic kidney disease.

  • Paricalcitol capsules (oral): approved for adults with CKD Stages 3 and 4, and CKD Stage 5 patients on hemodialysis or peritoneal dialysis
  • Zemplar capsules (oral): approved for adults AND pediatric patients ages 10 to 16 with CKD Stages 3, 4, and 5, including those on hemodialysis or peritoneal dialysis
  • Paricalcitol injection (intravenous): approved for adults and pediatric patients age 5 and older with CKD who are on dialysis
  • Zemplar injection (intravenous): approved for adults and pediatric patients age 5 and older with CKD who are on dialysis
⚙️How it works▾

When the kidneys are damaged by chronic kidney disease, they can no longer properly activate vitamin D. Without enough active vitamin D, the parathyroid glands ramp up PTH production — this is secondary hyperparathyroidism. High PTH disturbs calcium and phosphorus balance and can damage bones over time. Paricalcitol is a synthetic, active form of vitamin D that binds to vitamin D receptors (VDR) in the parathyroid gland and other tissues, directly reducing the amount of PTH the glands produce and release.

By restoring vitamin D receptor activity, paricalcitol helps bring PTH levels back toward a healthy range and supports better control of calcium and phosphorus — which is critical for bone health in kidney disease.

💊How it's taken▾

Paricalcitol is available as an oral capsule or an intravenous injection, and the two forms are used in different clinical settings. Capsules are taken by mouth — either once daily or three times a week (never more often than every other day when on a three-times-weekly schedule) — and can be taken with or without food. Injections are given through the hemodialysis access line during dialysis and are administered no more often than every other day. Your prescriber calculates your starting dose based on your PTH level and adjusts it regularly using PTH, calcium, and phosphorus lab results — always follow their current instructions and never adjust your own dose.

🤒Side effects — in detail▾

The most commonly reported side effects with paricalcitol include:

  • Diarrhea
  • Nausea or vomiting
  • Dizziness or vertigo
  • High blood pressure (hypertension)
  • Swelling (edema)
  • Hypersensitivity (allergic-type) reactions
  • Headache
  • Nasopharyngitis (runny nose or cold-like symptoms)

More serious reactions — including high calcium levels (hypercalcemia), which can cause heart rhythm problems, confusion, or seizures — require prompt medical attention. Tell your doctor right away if you notice unusual tiredness, confusion, excessive thirst, or frequent urination.

⚠️Warnings & precautions▾
  • Hypercalcemia (high blood calcium): The most important risk. It can cause heart arrhythmias, seizures, and — with long-term elevation — calcium deposits in blood vessels and soft tissues. Risk increases if you also take calcium supplements, thiazide diuretics, or other vitamin D products. Calcium levels should be checked frequently, especially when starting or adjusting the dose.
  • Digitalis toxicity: If you take digoxin or similar heart medications, high calcium from paricalcitol can make those drugs more toxic. Extra monitoring of calcium and heart symptoms is needed.
  • Adynamic bone disease: Over-suppressing PTH for too long can leave bones dangerously inactive and raise fracture risk. Your PTH levels must be monitored regularly so the dose can be adjusted to avoid going too low.
  • Allergic reactions: Serious hypersensitivity reactions, including swelling of the throat (angioedema) and hives, have been reported.
🔀What it interacts with▾

Paricalcitol can interact with several medications and substances that affect calcium levels or how the drug is processed in the body:

  • Calcium supplements (high-dose): Can push calcium levels dangerously high when combined with paricalcitol
  • Other vitamin D products: Compound the effect and increase hypercalcemia risk
  • Thiazide diuretics (e.g., hydrochlorothiazide): Reduce the kidneys' ability to excrete calcium, raising blood calcium further
  • Digitalis compounds (e.g., digoxin): High calcium caused by paricalcitol increases the risk of digitalis toxicity — closer monitoring is essential
  • Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, and others): Slow the breakdown of paricalcitol in the liver, raising its blood levels; a dose adjustment may be needed
  • Grapefruit juice: May also inhibit CYP3A enzymes and increase paricalcitol exposure

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

📋Before taking it▾
  • Do not use paricalcitol if you currently have hypercalcemia (high blood calcium) or vitamin D toxicity
  • Do not use if you have a known allergy to paricalcitol or any of its inactive ingredients; serious allergic reactions including throat swelling have been reported
  • Tell your prescriber about all medications — especially digoxin, calcium supplements, thiazide diuretics, other vitamin D products, and any antifungal, antibiotic, or HIV medications that may inhibit CYP3A
  • Pregnancy: Animal studies showed some risk of fetal harm at high doses; there is limited human data. Chronic kidney disease itself also carries risks during pregnancy. Discuss the benefits and risks with your doctor
  • Breastfeeding: Paricalcitol and/or its breakdown products may pass into breast milk. Breastfeeding is not recommended during treatment because of the potential for serious side effects, including hypercalcemia, in the infant
  • Children: Zemplar capsules are approved for ages 10–16; paricalcitol and Zemplar injections are approved for ages 5 and older. Safety and effectiveness in children under these age thresholds have not been established
  • Older adults (65+): No differences in overall safety or effectiveness were seen in clinical studies compared to younger patients, though greater individual sensitivity cannot be ruled out
  • Tell your doctor if you have liver problems — mild to moderate hepatic impairment does not require a dose change, but severe hepatic impairment has not been studied
🚑If you take too much▾

Taking too much paricalcitol can cause hypercalcemia (dangerously high calcium), high phosphorus (hyperphosphatemia), high calcium in the urine (hypercalciuria), and excessive suppression of PTH. If an overdose is suspected, seek medical attention right away — your care team may monitor your calcium, electrolytes, heart rhythm, and urinary calcium closely. Paricalcitol is not significantly removed by dialysis, so early supportive treatment is important.

📡Pharmacodynamics — effects in the body▾

Paricalcitol lowers levels of intact PTH (parathyroid hormone) in the blood while also raising serum calcium and phosphorus — effects seen in both hemodialysis and peritoneal dialysis patients. The goal is to bring PTH into a target range: enough reduction to control secondary hyperparathyroidism, but not so much that bones become abnormally inactive (adynamic bone disease). Doses are calculated and adjusted using PTH, calcium, and phosphorus lab values to keep these effects in balance.

🔬Pharmacokinetics — how your body processes it▾

When taken as a capsule, paricalcitol is well absorbed — about 72–86% of the dose reaches the bloodstream — and food does not meaningfully change the total amount absorbed. It is very tightly bound to proteins in the blood (over 99%) and is broken down mainly in the liver by enzymes including CYP3A4. The drug is eliminated mostly through the bile and stool (about 70%) with a smaller amount in urine. In healthy adults the drug's half-life (the time for blood levels to drop by half) is 4–6 hours, but in people with CKD Stages 3–5 this extends to 14–20 hours, meaning the drug stays active longer in the body.

📦How to store it▾

Store paricalcitol capsules at 20°-25°C (68°-77°F) . Protect from light.

📄 Written from Paricalcitol’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →

🩺 Pharmacist Counseling Corner

Quick, plain-English answers to the questions patients ask most about Paricalcitol — the kind of thing our pharmacy team would talk through with you at the counter.

What exactly is paricalcitol doing for my kidneys? ▾
Paricalcitol isn't repairing your kidneys directly — what it's doing is fixing a problem caused by kidney disease. When your kidneys are damaged, they can't activate vitamin D the way they should, and that causes your parathyroid glands to overproduce a hormone called PTH. Too much PTH over time throws off your calcium and phosphorus levels and harms your bones. Paricalcitol is a form of active vitamin D that steps in, binds to receptors in your parathyroid glands, and tells them to slow down PTH production.
How will I know if my calcium gets too high while I'm on this medication? ▾
High calcium — called hypercalcemia — can sneak up on you, but there are signs to watch for: feeling unusually tired or weak, trouble thinking clearly, loss of appetite, nausea, vomiting, constipation, being extra thirsty, urinating more than usual, or losing weight without trying. If you notice any of those, call your doctor right away. Your care team will also be doing regular blood tests to keep an eye on your calcium levels, especially when you first start the medication or after any dose changes.
Can I take my calcium supplements or vitamin D while on paricalcitol? ▾
You need to check with your prescriber before continuing or starting any calcium supplements or other vitamin D products. Taking them alongside paricalcitol raises your risk of getting too much calcium in your blood, which can be dangerous. Your doctor will want to know exactly what you're taking so they can adjust your monitoring or your doses accordingly.
I take digoxin for my heart. Is it safe to use paricalcitol too? ▾
You can use them together, but it does require closer monitoring. Paricalcitol can raise your calcium levels, and high calcium makes digoxin more likely to reach toxic levels in your body — that's a real risk. Your care team will check your calcium more frequently and watch you for any signs of digoxin toxicity, such as nausea, visual changes, or irregular heartbeat. Just make sure your cardiologist and kidney doctor are both aware you're on both medications.
Is it safe to breastfeed while taking paricalcitol? ▾
It's not recommended. The drug and its byproducts may pass into breast milk, and there's a concern that this could cause high calcium levels in a nursing baby. Until more is known, the guidance is to avoid breastfeeding during treatment. Talk to your doctor so you can weigh your options and make the best decision for you and your baby.
My doctor keeps adjusting my dose — why doesn't it just stay the same? ▾
That's actually the medication working as it should. Paricalcitol is a precision tool — your dose is calculated based on your PTH levels and fine-tuned using your calcium and phosphorus lab results. PTH levels can shift over time with your kidney disease or dialysis, so the dose needs to follow. The goal is to keep PTH in the right zone: low enough to control the problem, but not so low that your bones become too inactive. Regular adjustments mean your team is paying close attention, which is a good thing.
Is Paricalcitol available over the counter? ▾
Paricalcitol is dispensed by prescription according to its FDA labeling, so it isn't sold over the counter. Your prescriber and pharmacist will determine if it's appropriate for you.
When was Paricalcitol first available? ▾
Paricalcitol has been available in the United States since at least 1998, based on FDA approval history (Drugs@FDA) and product marketing records.
Who makes Paricalcitol? ▾
Paricalcitol is supplied by 23 manufacturers listed in the FDA NDC Directory, including Amneal Pharmaceuticals LLC, AbbVie Inc., Bryant Ranch Prepack.

💬 Answers drafted from Paricalcitol’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →

🧰 Keep exploring

🌿Drug & Supplement CheckerParicalcitol vs. vitamins & herbs 💬Ask a PharmacistFree answer, usually < 24h 🔎NDC & pricing lookupFind Paricalcitol NDCs & costs 🅰️Browse Drugs A–ZLook up any medication

💊 How Paricalcitol comes

Paricalcitol is available in 2 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Capsule

By mouth
Brands Zemplar
How this form is used
What it may be used for
  • Paricalcitol capsules are approved for adults to prevent and treat secondary hyperparathyroidism associated with CKD Stages 3, 4, and 5 (including patients on hemodialysis or peritoneal dialysis)
  • Zemplar capsules are also approved for pediatric patients ages 10 to 16 years with CKD Stages 3, 4, and 5 (including those on hemodialysis or peritoneal dialysis)
Important instructions
  • Paricalcitol and Zemplar capsules are taken by mouth — either once daily or three times a week, depending on your CKD stage and your prescriber's instructions
  • When taking capsules three times a week, doses should not be given more frequently than every other day
  • Zemplar capsules can be taken with or without food; a high-fat meal does not change total absorption but may delay the time it takes to reach peak levels by about 2 hours
  • Your dose will be adjusted based on regular lab results for PTH, calcium, and phosphorus — always follow your prescriber's current instructions
Available strengths 3 strengths
1 mcg 2 mcg 4 mcg
60 FDA-listed product records ⓘ

Injection

Into a vein
Brands Zemplar
How this form is used
What it may be used for
  • Paricalcitol injection is approved for adults and pediatric patients age 5 and older with CKD on dialysis to prevent and treat secondary hyperparathyroidism
  • Zemplar injection is approved for adults and pediatric patients age 5 and older with CKD on dialysis to prevent and treat secondary hyperparathyroidism
Important instructions
  • Paricalcitol injection and Zemplar injection are given intravenously through the hemodialysis vascular access line at any time during a dialysis session
  • Paricalcitol injection should not be injected directly into a vein outside of the dialysis access
  • Doses are given no more frequently than every other day; your care team will set the schedule based on your PTH and calcium lab results
  • Calcium levels are typically checked twice a week when starting or adjusting the injection dose, and PTH is checked every 2 to 4 weeks
Available strengths 3 strengths
2 mcg/mL 5 mcg/mL 10 mcg/2 mL
45 FDA-listed product records ⓘ

📊 Paricalcitol across the U.S. market

How Paricalcitol appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

2
Dose forms ⓘ
23
Manufacturers
2
Brand names
111
FDA-listed product records ⓘ
1998
First marketed ⓘ

FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

Also listed with the FDA, not a patient dose form: Powder (6) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.

Amneal Pharmaceuticals LLC19%
AbbVie Inc.11%
Bryant Ranch Prepack9%
Aurobindo Pharma Limited8%
Eugia US LLC7%
Bionpharma Inc.5%
Other makers41%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

📈 How widely Paricalcitol is used

A general measure of how commonly Paricalcitol is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.

Think of this as a proxy for how widely Paricalcitol is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.

120,979
Medicaid prescriptions filled (Q1–Q4 2025)
$5.9M gross Medicaid reimbursement (before mandatory rebates — net cost is lower)

How commonly is Paricalcitol prescribed? Of the 1,596 medications we measure, Paricalcitol ranks #479 by Medicaid prescriptions — more than 70% of them.

Where Paricalcitol ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5
Total prescriptions — #479 of 1,596
#474 Adapalene 126,305 Rx #475 Misoprostol 125,269 Rx #476 Glucagon Injection 123,688 Rx #477 Olanzapine and Samidor... 123,672 Rx #478 Olanzapine / Samidorph... 123,672 Rx #479 Paricalcitol 120,979 Rx #480 Risperidone Injection 120,886 Rx #481 Testosterone Transderm... 120,370 Rx #482 Mometasone Oral Inhala... 119,971 Rx #483 Clarithromycin 119,512 Rx #484 Azathioprine 118,943 Rx

Utilization by Paricalcitol product

Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.

The 1 mL / 0.005 mg/mL injection is the most-dispensed Paricalcitol product — about 68% of these Medicaid prescriptions.

1 ML paricalcitol 0.005 MG/ML Injection Most dispensed

82,272 Medicaid prescriptions (Q1–Q4 2025) 68% of Paricalcitol prescriptions shown $2.5M gross reimbursement (before rebates) ≈ $30 per prescription (gross)

Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736919

paricalcitol 0.005 MG/ML Injectable Solution

29,218 Medicaid prescriptions (Q1–Q4 2025) 24% of Paricalcitol prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $58 per prescription (gross)

Summed across the 2 of 14 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 200321

1 ML paricalcitol 0.002 MG/ML Injection

8,553 Medicaid prescriptions (Q1–Q4 2025) 7% of Paricalcitol prescriptions shown $1.7M gross reimbursement (before rebates) ≈ $194 per prescription (gross)

Summed across the 3 of 13 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1736931

paricalcitol 0.001 MG Oral Capsule

840 Medicaid prescriptions (Q1–Q4 2025) <1% of Paricalcitol prescriptions shown $28,984 gross reimbursement (before rebates) ≈ $35 per prescription (gross)

Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 577315

paricalcitol 0.002 MG Oral Capsule

96 Medicaid prescriptions (Q1–Q4 2025) <1% of Paricalcitol prescriptions shown $26,778 gross reimbursement (before rebates) ≈ $279 per prescription (gross)

Summed across the 2 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 577317

Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.

Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Paricalcitol, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 12 of 74 listed Paricalcitol NDCs with Medicaid activity.

🔍 Compare Paricalcitol products

A representative set of FDA-listed product records for Paricalcitol — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Showing 111 of 111 products — FDA National Drug Code Directory. See every product, package size and price: browse all 111 Paricalcitol NDCs →

RxNorm Concept Web — From Ingredient to Every Form and Strength

This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.

Ingredient (IN) Paricalcitol RxCUI 73710 3 dose forms · 8 strengths
  1. Dose form (SCDF) Injectable Solution RxCUI 378380 In current FDA listings
    Clinical drug / strength (SCD) 0.002 MG/ML RxCUI 351154 0.005 MG/ML RxCUI 200321
  3. Dose form (SCDF) Oral Capsule RxCUI 577314 In current FDA listings
    Clinical drug / strength (SCD) 0.001 MG RxCUI 577315 0.002 MG RxCUI 577317 0.004 MG RxCUI 577324

Look up RxCUI 73710 in the RxCUI Atlas →

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

🏷️ Sold under these brand names

Zemplar

🏭 Manufacturers & labelers

Amneal Pharmaceuticals LLC 21 AbbVie Inc. 12 Bryant Ranch Prepack 10 Aurobindo Pharma Limited 9 Eugia US LLC 8 Bionpharma Inc. 6 Time Cap Laboratories, Inc 6 Accord Healthcare, Inc. 4 AuroMedics Pharma LLC 4 Dr. Reddy's Laboratories, Inc. 4 Mylan Institutional LLC 4 Zydus Pharmaceuticals USA Inc 3 West-Ward Pharmaceuticals Corp 3 Patheon Softgels Inc. 3 Marksans Pharma Limited 3 Dr. Reddy's Laboratories Limited 3 Catalent Pharma Solutions, LLC 2 Formosa Laboratories, Inc. 1 Neuland Laboratories Limited 1 Sai Life Sciences Limited 1 Sigma-Aldrich Corporation 1 Chongqing Huapont Pharmaceutical Co Ltd 1 AbbVie Ireland NL B.V. 1

RxNorm drug class

Paricalcitol belongs to the Vitamin D Analog class.

Pharmacologic class Vitamin D Analog, Vitamin D2 Analog
Drug family (ATC) Other anti-parathyroid agents

Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.

🔬 Where this comes from

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. ✓ Linked label effective Aug 7, 2024
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Paricalcitol.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.
🧾 Clinical label set — FDA-filed SPL labels retained for Paricalcitol after exact ingredient or ingredient-combination matching and applicable route/form matching
Clinical labels in scope
11
NDC products indexed
111
Distinct labelers/manufacturers represented
23
Linked representative label ⓘ
AbbVie Inc.
Linked label effective
Aug 7, 2024
Composite sections available
21
Linked SPL Set ID
1b27c026-2d60-47b4-2a9c-ded1818f21b5
Linked SPL Document ID
3a66f348-5e7b-4188-affc-2083900602ea
Open the linked representative label on DailyMed ↗

How we combine label and product data

HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 11 FDA-filed SPL label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.

For canonical ingredient pages, bounded product-attributed indication and administration excerpts may be added to the AI evidence, and the generator is instructed to preserve available product, brand, route, and form qualifiers instead of treating one label as universal. Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. AbbVie Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.

This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.